{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:38:48Z","timestamp":1761806328145,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"vor","delay-in-days":5428,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1016\/j.nurt.2008.08.006","type":"journal-article","created":{"date-parts":[[2008,10,4]],"date-time":"2008-10-04T15:11:21Z","timestamp":1223133081000},"page":"579-582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Therapeutic Options in Other Metabolic Myopathies"],"prefix":"10.1016","volume":"5","author":[{"given":"Matthias","family":"Vorgerd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nurt.2008.08.006_bib1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.nmd.2007.03.001","article-title":"144th ENMC International Workshop: outcome measures in McArdle disease","volume":"17","author":"Quinlivan","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nurt.2008.08.006_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003458.pub3","article-title":"Pharmacological and nutritional treatment for McArdle disease (glycogen storage disease type V)","volume":"2","author":"Quinlivan","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.nurt.2008.08.006_bib3","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.mam.2004.06.004","article-title":"Carnitine palmitoyltransferase 1 and 2: biochemical, molecular and medical aspects","volume":"25","author":"Bonnefont","year":"2004","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.nurt.2008.08.006_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004760.pub2","article-title":"Creatine for treating muscle disorders","volume":"1","author":"Kley","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.nurt.2008.08.006_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1365-201x.1999.00539.x","article-title":"Creatine uptake in isolated soleus muscle: kinetics and dependence on sodium, but not on insulin","volume":"166","author":"Willott","year":"1999","journal-title":"Acta Physiol Scand"},{"key":"10.1016\/j.nurt.2008.08.006_bib6","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1001\/archneur.57.7.956","article-title":"Creatine therapy in myophosphorylase deficiency (McArdle's disease): a placebo controlled crossover trial","volume":"57","author":"Vorgerd","year":"2000","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2008.08.006_bib7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/archneur.59.1.97","article-title":"Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle's disease: double-blind, placebo-controlled crossover trial","volume":"59","author":"Vorgerd","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2008.08.006_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/adc.2008.146548","article-title":"Carbohydrate- and protein-rich diets in McArdle disease: effect on exercise capacity","author":"Andersen","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.nurt.2008.08.006_bib9","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/ana.20881","article-title":"Aerobic conditioning: an effective therapy in McArdle's disease","volume":"59","author":"Haller","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2008.08.006_bib10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/ana.10499","article-title":"Phenoytype modulators in myophosphorylase deficiency","volume":"53","author":"Martinuzzi","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nurt.2008.08.006_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.neulet.2007.06.025","article-title":"Genotype modulators of clinical severity in McArdle disease","volume":"422","author":"Rubio","year":"2007","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.nurt.2008.08.006_bib12","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/mus.20937","article-title":"Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease","volume":"37","author":"Martinuzzi","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nurt.2008.08.006_bib13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1212\/01.wnl.0000194212.31318.fc","article-title":"Gentamicin treatment in McArdle disease: failure to correct myophosphorylase deficiency","volume":"66","author":"Schroers","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.08.006_bib14","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/archneur.65.6.786","article-title":"Effect of oral sucrose shortly before exercise on work capacity in McArdle disease","volume":"65","author":"Andersen","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nurt.2008.08.006_bib15","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1212\/WNL.59.7.1046","article-title":"Exercise tolerance in carnitine palmitoyltransferase II deficiency with IV and oral glucose","volume":"59","author":"Orngreen","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.08.006_bib16","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1212\/01.WNL.0000078195.05396.20","article-title":"Effect of diet on exercise intolerance in carnitine palmitoyltransferase II deficiency","volume":"61","author":"Orngreen","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.nurt.2008.08.006_bib17","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1203\/01.PDR.0000083001.91588.BB","article-title":"Correction of fatty acid oxidation in carnitine palmitoyltransferase 2-deficient cultured skin fibroblasts by bezafibrate","volume":"54","author":"Djouadi","year":"2003","journal-title":"Pediatr Res"},{"key":"10.1016\/j.nurt.2008.08.006_bib18","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1210\/jc.2004-1936","article-title":"Peroxisome proliferator activated receptor delta (PPARdelta) agonist but not PPARalpha corrects carnitine palmitoyl transferase 2 deficiency in human muscle cells","volume":"90","author":"Djouadi","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.nurt.2008.08.006_bib19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1172\/JCI0215311","article-title":"Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride","volume":"110","author":"Roe","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nurt.2008.08.006_bib20","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s10545-006-0290-3","article-title":"Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential","volume":"29","author":"Roe","year":"2006","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.nurt.2008.08.006_bib21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/cc2978","article-title":"Bench-to-bedside review: Rhabdomyolysis\u2013an overview for clinicians","volume":"9","author":"Huerta-Alardin","year":"2005","journal-title":"Crit Care"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923004609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923004609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1016\/j.nurt.2008.08.006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:38:01Z","timestamp":1761806281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923004609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["S1878747923004609"],"URL":"https:\/\/doi.org\/10.1016\/j.nurt.2008.08.006","relation":{},"ISSN":["1878-7479"],"issn-type":[{"type":"print","value":"1878-7479"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Options in Other Metabolic Myopathies","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nurt.2008.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}